INTELENCE

LOE Approaching

etravirine

NDAORALTABLETPriority Review
Approved
Jan 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

Non-Nucleoside Reverse Transcriptase Inhibitors

Pharmacologic Class:

Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor

Clinical Trials (5)

NCT04630002Phase 1Completed

Drug-drug Interaction (DDI) Study of GSK3640254 With Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR)

Started Oct 2020
54 enrolled
HIV Infections
NCT04208373Phase 1Completed

A Study to Assess the Effects of Itraconazole and Etravirine on JNJ-64417184 in Healthy Adult Participants

Started Dec 2019
32 enrolled
Healthy
NCT04194021N/AUnknown

Characteristics and Outcomes of Patients Who Received Etravirine and/or Darunavir

Started Jan 2019
871 enrolled
HIV/AIDS
NCT02212379Phase 2Completed

Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL

Started Jan 2015
170 enrolled
HIV-1 Infection
NCT02063360Phase 1Completed

DDI Study of BMS-663068 With Etravirine (ETR) and/or Darunavir (DVR) + Ritonavir (RTV)

Started Feb 2014
42 enrolled
Infection, Human Immunodeficiency Virus